Drug Database
SI

simvastatin + triflusal (IRIST stent)

✓ Approved

Palau Pharma · HMGCR · Small Molecule

What is simvastatin + triflusal?

simvastatin + triflusal is a small molecule developed by Palau Pharma. It is approved for therapeutic indications via surgical implantation.

Drug Profile

Brand NamesIRIST stent
CompanyPalau Pharma
Drug ClassSmall Molecule
Molecular TargetHMGCR, PDE4A, PDE4B, PDE4C, PDE4D, PTGS1, PTGS2
RouteSurgical Implantation
StatusApproved
Sources: ClinicalTrials.gov, Palau Pharma

Mechanism of Action

Molecular Targets

simvastatin + triflusal acts on 7 molecular targets:

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, MYPLG)
PDE4Aphosphodiesterase 4A (PDE4, DPDE2)
PDE4Bphosphodiesterase 4B (PDEIVB, DPDE4)
PDE4Cphosphodiesterase 4C (DPDE1, PDE21)
PDE4Dphosphodiesterase 4D (PDE43, STRK1)
PTGS1prostaglandin-endoperoxide synthase 1 (PCOX1, COX3)
PTGS2prostaglandin-endoperoxide synthase 2 (PHS-2, GRIPGHS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

simvastatin + triflusal is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Injury, poisoning and procedural complicationsRestenosis✓ Approved

Related Research Articles

PubMedAnnals of vascular diseases2026-09-19

Use of EN Snare Device for Successful Retrieval of a Pigtail Catheter Straightener after Iliac Artery Stent Placement: A Case Report.

Wada Takeshi T, Takayama Katsutoshi K, Myouchin Kaoru K

Percutaneous retrieval is a well-established, minimally invasive method for removing foreign bodies from blood vessels. We experienced a 77-year-old man in whom a radiolucent pigtail catheter straightener had been mis-inserted into the abdominal aorta and was successfully retrieved using an EN Snare device. This report demonstrates that operators must remain aware of the risk of accidentally inserting pigtail catheter straighteners into blood vessels.

PMID 42760962
Read full article →
PubMedMedicine2026-09-19

Analysis, evaluation of hemodynamic differences and treatment strategy recommendations for multiple paraclinoid aneurysms.

Zhao Xianying X, Wang Jiahao J, Gao Chao C, Gao Shang S et al.

Multiple paraclinoid aneurysms of the internal carotid artery present distinct clinical and anatomical challenges compared with other aneurysms. This study aimed to investigate the hemodynamic characteristics of the parent artery adjacent to these lesions and to provide evidence-based suggestions for clinical treatment. We retrospectively reviewed digital subtraction angiography images of 57 patients treated between 2020 and 2024, including 18 cases with multiple paraclinoid aneurysms, 19 with a single paraclinoid aneurysm, and 20 with normal vascular anatomy. Parameters including peak systolic flow velocity and wall shear stress were derived from reconstructed hemodynamic models. We compared hemodynamic profiles among groups and evaluated the effects of simulated aneurysm obliteration on the distal vessel wall proximal to the carotid bifurcation. Four real-world follow-up cases were also analyzed for morphological and hemodynamic changes after treatment. The multiple-aneurysm group exhibited greater variability and instability in wall shear stress and flow velocity than the single-aneurysm and normal groups. Simulated aneurysm elimination showed no significant hemodynamic effect on distal vessels (P > .05). In clinical follow-up, however, noticeable morphological and hemodynamic alterations were observed following stent deployment. Multiple paraclinoid aneurysms induce more prominent hemodynamic disturbances in the parent artery. Aneurysm obliteration appears to have minimal immediate impact on the distal vessel wall, but stent placement may produce favorable long-term vascular remodeling, including straightened curvature and improved mild stenosis.

PMID 42760743
Read full article →
PubMedNeuroradiology2026-09-19

Pipeline Shield versus Pipeline Flex for unruptured intracranial aneurysms: a propensity-matched multicenter study.

Ge Runze R, Peng Chao C, Chen Wenxin W, Chen Guangzhong G et al.

Pipeline Flex Embolization Device with Shield Technology (PED Shield) is designed to reduce the incidence of thrombosis events through phosphorylcholine coating. However, the comparative efficacy and safety of PED Shield and PED/PED Flex remain unclear. We conducted a retrospective analysis of a prospectively maintained database at three advanced stroke centers from February 2016 to October 2024. Propensity score matching was employed to adjust for sex, age, hypertension, diabetes, hyperlipidemia, smoking, aneurysm location, morphology, size, coiling and follow-up duration. After matching, perioperative complications and clinical and angiographic outcomes were compared. 1039 patients treated by PED/PED Flex and 172 patients treated by PED Shield were enrolled. For clinical outcomes, 164 pairs were matched. No significant differences were found in total perioperative complications (7.9% vs. 4.9%, p = 0.259) and favourable prognosis (mRS score 0-2, 98.0% vs. 97.5%, p = 0.760) between the PED Shield and PED/PED Flex group. For angiographic outcomes, 121 pairs were matched. No significant differences were observed in complete occlusion (80.2% vs. 73.6%, p = 0.223), significant in-stent stenosis (ISS, ISS rate > 50%) (3.3% vs. 5.0%, p = 0.749) and symptomatic ISS (0.0% vs. 2.5%, p = 0.247) between the PED Shield and PED/PED Flex group. However, PED Shield had a lower incidence of ISS (ISS rate ≥ 25%, 5.0 vs. 14.9%, p = 0.010) at a mean follow-up time of 6-7 months. Compared with PED/PED Flex, PED Shield has a lower rate of ISS at a mean follow-up time of 6-7 months. No significant differences are observed in perioperative complications, clinical outcomes, complete occlusion, significant ISS and symptomatic ISS. URL: https://www. gov ; Unique identifier: NCT06446778.

PMID 42760406
Read full article →
PubMedFrontiers in neurology2026-09-19

Safety, efficacy, and angiographic outcomes of endovascular coiling for very small unruptured intracranial aneurysms (≤ 3 mm): subgroup analysis of the ECOSA registry.

Ashouri Yazan Y, Tariq Zain Z, AlMajali Mohammad M, Kareem Mustafa Abdul MA et al.

Very small unruptured intracranial aneurysms (VSUIAs) measuring ≤ 3 mm represent a unique clinical challenge, balancing the low but non-negligible lifetime risk of rupture against the procedural risks of endovascular intervention. This study reports the safety, efficacy, and angiographic outcomes of endovascular coiling for VSUIAs from the ECOSA (Endovascular Coiling of Small Aneurysms) multicenter registry. We performed a subgroup analysis of the ECOSA multicenter registry of patients with VSUIAs (maximum diameter ≤ 3 mm) who underwent endovascular coiling. Patient demographics, aneurysm characteristics, procedural details, periprocedural complications, clinical outcomes (modified Rankin Scale; mRS), and angiographic follow-up data were analyzed. A total of 116 patients with 116 VSUIAs underwent endovascular coiling. The mean age was 52.3 years (SD 12.1), and the majority were female (75.0%). The mean aneurysm diameter was 2.66 mm (SD 0.44) and mean neck diameter was 2.1 mm (SD 0.87). Most aneurysms were discovered incidentally (78.4%). Balloon-assisted coiling was used in 14.7% and stent-assisted coiling in 23.3% of cases. The thromboembolic event (TEE) rate was 1.7%, with no symptomatic events. Intraprocedural rupture occurred in 0.9% of cases with no intraprocedural mortality. Among 98 patients with clinical follow-up (median 7.75 months), 93.9% of patients achieved good functional outcomes (mRS 0-2), and all-cause mortality rate was 1.0%. Among 80 patients with angiographic follow-up (median 6 months), adequate occlusion (RROC I-II) was achieved in 86.3%. Endovascular coiling of VSUIAs ≤ 3 mm is feasible and associated with a low complication rate, high rates of good functional outcomes, and durable angiographic occlusion. These findings support the safety of elective intervention in carefully selected patients with high-risk morphological or clinical features. Larger prospective studies are needed to define optimal patient selection criteria for VSUIAs.

PMID 42760949
Read full article →
PubMedJournal of molecular histology2026-09-18

Quercetin alleviates statin-induced myopathy in adult male rats: insights into the role of oxidative stress, apoptosis, and autophagy-related gene expression (LC3 and LAMP2).

Ahmed Shaimaa A G SAG, Abdelhaffez Azza S AS, Ali Rasha M RM, Ismaiel Amany M AM et al.

Statins, anti-hyperlipidemic drugs, are associated with skeletal muscle myopathy. New strategies to preserve muscle strength in statin-induced myopathy (SIM) are needed. This study assessed the effect of quercetin on simvastatin-induced myopathy in adult male rats, focusing on the modulation of autophagy-apoptosis crosstalk. Forty adult albino male rats were randomly divided into four groups. The control group (C) received distilled water, the quercetin group (Q) received quercetin (50 mg/kg/day, orally), the simvastatin (S) group received simvastatin (80 mg/kg/day, orally), and the quercetin + simvastatin (Q + S) group received both quercetin (50 mg/kg/day) and simvastatin (80 mg/kg/day, orally), all for 30 days. Gastrocnemius muscle contractility, muscle weight/tibial length ratio, histopathological examination, serum creatine kinase (CK) levels, oxidative stress markers, lipid profile, autophagy-related gene expression (LC3 and LAMP2), and apoptosis markers (BAX and caspase-3) were evaluated. Simvastatin induced muscle atrophy and significantly elevated serum CK levels. These changes were associated with increased oxidative stress, altered expression of autophagy-related genes (increased LC3 and decreased LAMP2), and increased expression of the apoptotic markers BAX and Caspase-3. Quercetin ameliorated these alterations by improving muscle contractility, reducing CK levels and oxidative stress, attenuating apoptosis, and modulating autophagy-related gene expression. Quercetin alleviated simvastatin-induced myopathy through its antioxidant and antiapoptotic effects and was associated with modulation of autophagy-related gene expression. These findings suggest that quercetin may represent a promising adjuvant strategy for mitigating statin-associated myopathy. Further studies evaluating autophagic flux at the protein level are warranted to clarify the underlying mechanisms.

PMID 42758399
Read full article →
PubMedJournal of vascular surgery cases and innovative techniques2026-09-18

Carotid stent infection caused by Burkholderia pseudomallei successfully treated with surgery.

Duong Thang Ngoc TN, Do Hien Thi Thu HTT, Nguyen Dan Van DV, Phung Son Duy Hong SDH et al.

Carotid stent infection is a rare but serious complication with potentially devastating consequences. We report the case of a 76-year-old man admitted with carotid stent infection, who underwent surgical removal of the stent and reconstruction of the common-internal carotid artery using an autologous saphenous vein graft. Microbiological cultures were positive for Burkholderia pseudomallei. The patient was discharged after 20 days of treatment in stable clinical condition with normalized laboratory examination. Surgical management provides an effective strategy for complete eradication of carotid stent infection and enables pathogen identification to guide targeted antibiotic therapy.

PMID 42756562
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about simvastatin + triflusal